Biosuccess Biotech Co. is a company founded in 2005 and pursues TPA (12-O-tetradecanoylphorbol-13-acetate) development in order to treat of AML and HIV. The two main researchers in this filed are Prof. Richard Chang & Prof. Zhang Tao Han. Clinical studies were conducted in China regarding acute myelogenous leukemia (AML). During the study some patients accomplished partial remission. Biosuccess Biotech posseses 20 years of exclusive rights to the usage of PD-616 both for treating acute myelogenous leukemia (AML) and HIV (AIDS). beginning January 30th, 2008. The Company has sole rights to the usage of the intravenous administration of PD-616. PD-616 must be given intravenously for therapeutic purposes, it cannot be administered orally or injected subcutaneously. Biosuccess Biotech has no knowledge of competing patents for using of PD-616 in treating acute myelogenous leukemia or AIDS.